All Oncology News

PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer

November 10th 2022

The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.

Neoantigen TCR T-cell Therapy Shows Early Proof-of-Concept in Solid Tumors

November 10th 2022

A personalized neoantigen-specific and off-the-shelf T cell receptor T-cell therapy utilized through CRISPR gene editing technology demonstrated feasibility and tolerability in 16 patients across multiple tumor types, according to first-in-human phase 1a findings.

Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies

November 10th 2022

FDA Approves Brentuximab Vedotin for Pediatric Patients With Previously Untreated, High-risk Hodgkin Lymphoma

November 10th 2022

The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide in pediatric patients aged 2 years and older with previously untreated, high-risk classical Hodgkin lymphoma.

Milademetan Shows Early Activity in MDM2-Amplified Advanced Solid Tumors

November 10th 2022

Milademetan monotherapy demonstrated preliminary antitumor activity in patients with MDM2-amplified and p53 wild-type advanced solid tumors.

Sequencing Strategies, Improving QOL Are Top Priorities in Neuroendocrine Neoplasm Treatment

November 10th 2022

Diane Reidy-Lagunes, MD, discussed the role of next-generation sequencing paired with systemic therapies and the option of peptide receptor radionuclide therapy in neuroendocrine malignancies.

Breast Cancer Advances in 2022 Shape CFS Agenda

November 10th 2022

Emerging novel therapies, new stratification factors, and sequencing challenges because of the new classifications for patients with breast cancer will be topics of discussion at the 40th Annual Chemotherapy Foundation Symposium® during the breast cancer sessions.

Addressing Intolerance and Resistance to BTK Inhibition Is Next Frontier in CLL Drug Development

November 9th 2022

The development of agents to address intolerance and acquired resistance to BTK inhibitors addresses 2 of the major unmet needs for patients with chronic lymphocytic leukemia.

Frontline NALIRIFOX Regimen Improves OS in Metastatic Pancreatic Ductal Adenocarcinoma

November 9th 2022

The NALIRIFOX regimen significantly improved overall survival over nab-paclitaxel plus gemcitabine in previously untreated patients with metastatic pancreatic ductal adenocarcinoma, meeting the primary end point of the phase 3 NAPOLI 3 trial.

Petrylak Previews Shift in Sequencing Paradigm in Urothelial Cancer

November 9th 2022

Daniel P. Petrylak, MD, highlights the use of checkpoint inhibitors, antibody-drug conjugates, and FGFR inhibitors in urothelial cancer and the current sequencing hurdles in the paradigm.

Dr. Robert Uzzo Appointed President and CEO of Fox Chase Cancer Center

November 9th 2022

Robert Uzzo, MD, MBA, FACS, has been formally named president and chief executive officer of Fox Chase Cancer Center following a period of interim leadership.

Innovations Are Poised to Lead MPN/MDS Treatment Landscape in a Positive Direction

November 9th 2022

Ahead of the 40th Annual Chemotherapy Foundation Symposium, Pinkal Desai, MD, addresses the evolving role of targeted therapies in MDS and how clinicians can characterize MDS risk.

40th Annual CFS® Highlights New Frontiers in Cancer Care

November 9th 2022

The Chemotherapy Foundation Symposium® returns to New York City for its 40th annual meeting with a 3-day program that will deliver the latest updates across the gamut of oncology care.

Pembrolizumab/Cabozantinib Combo Shows Promising Clinical Benefit in Recurrent Metastatic HNSCC

November 9th 2022

Nabil F. Saba, MD, FACP, expanded on efficacy data from a phase 2 trial investigating pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma and current challenges and safety concerns in selecting patients for evaluation.

FDA Approves Cemiplimab-rwlc Plus Platinum-based Chemotherapy for Advanced NSCLC

November 8th 2022

The FDA has approved cemiplimab-rwlc (Libtayo) in combination with platinum-based chemotherapy in adult patients with advanced non–small cell lung cancer with no EGFR, ALK, or ROS1 aberrations.

Clinical End Points and Trial Designs Undergo Evolution in RCC

November 8th 2022

Chung-Han Lee, MD, PhD, outlines common clinical trial end points in renal cell carcinoma and those that may provide a more complete picture of a drug’s activity, particularly as the standard of care evolves.

NICE Recommends Neoadjuvant Pembrolizumab/Chemotherapy, Followed by Adjuvant Pembrolizumab for TNBC

November 8th 2022

The National Institute for Health and Care Excellence has issued final guidance supporting use of neoadjuvant pembrolizumab in combination with chemotherapy, followed by adjuvant pembrolizumab, for adults with triple-negative breast cancer.

CAR T-Cell Therapies Improve Treatment Landscape in Relapsed/Refractory Multiple Myeloma

November 8th 2022

The increasing integration of CAR T-cell therapies into the treatment paradigm for adult patients with relapsed or refractory multiple myeloma addresses several unmet needs and improves outcomes for this historically limited patient population.

Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse

November 8th 2022

A targeted therapy for children with high-risk Hodgkin lymphoma was shown to significantly reduce relapse rates when tested in a clinical trial conducted by the Children’s Oncology Group and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children’s Healthcare of Atlanta and Winship Cancer Institute of Emory University.

DREAMSeq Trial Clarifies Treatment Sequencing in BRAF V600–Mutant Melanoma

November 8th 2022

Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations.